Once weekly dosing not enough of an advantage to justify marketing Merck’s DPP-4 inhibitor Marizev in the US and EU for type 2 diabetes.
By Kevin Shannon, Analyst
20 July 2016
I am an analyst at Datamonitor Healthcare, currently located in San Diego, California, where I am a member of the cardio...
Read full bio
Marizev’s once-weekly dosing is unlikely to provide it with an advantage over currently marketed oral antidiabetics as administration and compliance are not issues associated with the DPP-IV inhibitor class. Therefore, Datamonitor Healthcare does not expect this limited advantage to aid Marizev’s uptake, considering that it lacks any other differentiation from competing DPP-IV inhibitors. Clinical trials have shown once-weekly Marizev to be non-inferior to once-daily Januvia in the treatment of type 2 diabetes (Merck & Co, 2014), although Marizev lacks the cardiovascular and safety data that has fortified physicians’ trust in Januvia in a class currently facing several safety concerns. Marizev will be required to demonstrate distinct advantages over established DPP-IV inhibitors in order to drive significant uptake in this highly competitive class. Once-weekly dosing certainly provides an advantage to specific patient groups, but it is unlikely to provide the intended solutions to broader unmet needs in the market and it excludes Marizev from use in FDC treatments. Marizev will be further limited by its potential patient population, as Merck & Co announced that it would not proceed with marketing applications for Marizev outside of Japan. This decision limits uptake of Marizev to a small portion of the type 2 diabetes markets analyzed, though the Japanese market is likely the only region in which Marizev has a chance to succeed. Current prescribing trends in Japan provide an environment in which a once-weekly DPP-IV inhibitor has a small advantage, rather than only disadvantages.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>